As of late August 2025, the U.S. stock market has shown resilience, with major indices closing higher despite political uncertainties and upcoming earnings reports from key players like Nvidia. In such a climate, investors often seek opportunities beyond the well-trodden paths of large-cap stocks. Penny stocks—typically representing smaller or newer companies—remain an intriguing option for those looking to uncover potential growth at a lower entry cost. While the term may seem dated, these stocks can still offer significant opportunities when backed by strong financials and promising business models.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Dingdong (Cayman) (DDL) | $2.19 | $484.33M | ✅ 5 ⚠️ 0 View Analysis > |
| ATRenew (RERE) | $4.62 | $1B | ✅ 3 ⚠️ 0 View Analysis > |
| Waterdrop (WDH) | $1.82 | $647.38M | ✅ 4 ⚠️ 0 View Analysis > |
| CuriosityStream (CURI) | $4.44 | $257.21M | ✅ 4 ⚠️ 2 View Analysis > |
| WM Technology (MAPS) | $1.17 | $196.67M | ✅ 4 ⚠️ 2 View Analysis > |
| Performance Shipping (PSHG) | $1.89 | $24.93M | ✅ 4 ⚠️ 2 View Analysis > |
| Table Trac (TBTC) | $4.85 | $21.11M | ✅ 2 ⚠️ 2 View Analysis > |
| BAB (BABB) | $0.93 | $6.81M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $3.90 | $90.63M | ✅ 3 ⚠️ 3 View Analysis > |
| Resources Connection (RGP) | $4.85 | $161.7M | ✅ 3 ⚠️ 1 View Analysis > |
Click here to see the full list of 385 stocks from our US Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Cerus (CERS)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Cerus Corporation is a biomedical products company with a market cap of $245.37 million.
Operations: The company generates revenue primarily from its Blood Safety segment, totaling $192.51 million.
Market Cap: $245.37M
Cerus Corporation, with a market cap of US$245.37 million, primarily generates revenue from its Blood Safety segment, totaling US$192.51 million. Despite being unprofitable, Cerus has a positive cash flow and sufficient cash runway for over three years. The company recently raised its 2025 revenue guidance to US$200-203 million due to strong performance in the first half of the year and secured additional funding from the U.S. Department of Defense for product development. Its management team is seasoned, and short-term assets exceed liabilities significantly, although debt levels have increased over five years.
- Unlock comprehensive insights into our analysis of Cerus stock in this financial health report.
- Evaluate Cerus' prospects by accessing our earnings growth report.
Allogene Therapeutics (ALLO)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases, with a market cap of $257.38 million.
Operations: Allogene Therapeutics, Inc. has not reported any revenue segments as it is focused on the clinical development and commercialization of genetically engineered allogeneic T cell therapies for cancer and autoimmune diseases.
Market Cap: $257.38M
Allogene Therapeutics, Inc., with a market cap of US$257.38 million, remains pre-revenue as it focuses on clinical trials for its allogeneic T cell therapies. Recent updates include the advancement of its ALPHA3 trial using standard fludarabine and cyclophosphamide for lymphodepletion, potentially simplifying treatment and accelerating enrollment. The company is debt-free with short-term assets significantly exceeding liabilities, providing a cash runway of 1.9 years if cash flow trends continue. Despite unprofitability and negative return on equity, Allogene's strategic shifts in trial design reflect promising developments in their pipeline initiatives across cancer and autoimmune diseases.
- Click here to discover the nuances of Allogene Therapeutics with our detailed analytical financial health report.
- Gain insights into Allogene Therapeutics' future direction by reviewing our growth report.
Chegg (CHGG)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Chegg, Inc. offers personalized learning support services aimed at enhancing academic, life, and job skills for students globally, with a market cap of approximately $138.66 million.
Operations: The company's revenue primarily comes from its Educational Services segment, specifically in Education & Training Services, generating $506.58 million.
Market Cap: $138.66M
Chegg, Inc., with a market cap of US$138.66 million, is currently unprofitable but has managed to reduce its debt-to-equity ratio significantly over the past five years. Despite a volatile share price and negative return on equity, Chegg maintains a cash runway exceeding three years due to positive free cash flow. Recent earnings results show a decrease in sales and net loss compared to the previous year, yet guidance for Q3 2025 anticipates revenue between US$75 million and US$77 million. Additionally, Chegg filed a shelf registration for common stock offerings worth US$7.35 million in June 2025.
- Jump into the full analysis health report here for a deeper understanding of Chegg.
- Gain insights into Chegg's outlook and expected performance with our report on the company's earnings estimates.
Turning Ideas Into Actions
- Navigate through the entire inventory of 385 US Penny Stocks here.
- Want To Explore Some Alternatives? AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Allogene Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com